about
Statin-induced diabetes: incidence, mechanisms, and implicationsCurrent and Emerging Uses of Statins in Clinical Therapeutics: A ReviewA pilot study to examine the correlation between cognition and blood biomarkers in a Singapore Chinese male cohort with type 2 diabetes mellitusRosuvastatin Treatment Affects Both Basal and Glucose-Induced Insulin Secretion in INS-1 832/13 CellsLipid, blood pressure and kidney update 2013.Safety of statins: an updateUnderstanding the social factors that contribute to diabetes: a means to informing health care and social policies for the chronically ill.Rho/Rho-associated coiled-coil forming kinase pathway as therapeutic targets for statins in atherosclerosis.JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses.Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial.Do statins interfere with lifestyle intervention in the prevention of diabetes in primary healthcare? One-year follow-up of the FIN-D2D project.Different effects of statins on induction of diabetes mellitus: an experimental study.Incident diabetes and statins: the blemish of an undisputed heavy weight champion?Statins and risk of treated incident diabetes in a primary care populationRisk of incident diabetes among patients treated with statins: population based study.Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.Strategies for preventing type 2 diabetes: an update for clinicians.A prospective study of statin use and mortality among 67,385 blacks and whites in the Southeastern United States.Diabetogenic effect of statins: a double-edged sword?Statins use is associated with poorer glycaemic control in a cohort of hypertensive patients with diabetes and without diabetes.Evaluation of colesevelam hydrochloride for the treatment of type 2 diabetes.A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.The role of homocysteine-lowering B-vitamins in the primary prevention of cardiovascular disease.An update on the benefits and risks of rosuvastatin therapy.Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications.Pathogenesis and management of the diabetogenic effect of statins: a role for adiponectin and coenzyme Q10?Statins and their increased risk of inducing diabetes.Risk-benefit analysis of use of statins for primary prevention of cardiovascular disease in subjects without diabetes.Long-Term Outcomes of Short-Term Statin Use in Healthy Adults: A Retrospective Cohort Study.Killing two birds with one stone, maybe: CETP inhibition increases both high-density lipoprotein levels and insulin secretion.[Lipid lowering therapy in geriatric patients].Effect of different doses of statins on the development of type 2 diabetes mellitus in patients with myocardial infarction.Statin Therapy and Risk of Diabetes Mellitus in Aging Patients With Heterozygous Familial Hypercholesterolemia or Familial Combined Hyperlipidemia: A 10-Year Follow-Up.Statin therapy on glycaemic control in type 2 diabetes: a meta-analysis.Statins and new onset of diabetes: which one outweighs risk or benefit?Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic AgentsIn Vitro
P2860
Q26740677-E522ED72-0A31-4B00-9D68-EA72C749A33DQ28076346-06B4F8D6-C59A-4965-9F51-1718CC2898A0Q28538677-130F73E1-3D76-46F1-9057-7E9F81FD14CAQ28550796-A015CF3F-0EDC-4D89-AFA7-E16A523D52FCQ33574532-C0518B1A-62D3-49F1-8C0B-396F97CAAAB0Q33949312-326C2252-7280-42EF-ACC2-5E3D1F71B31DQ34346526-802C02FA-2B00-4238-AAC8-412073ADA337Q34362144-2E237743-BE62-4064-987E-1E0701851C58Q35172886-53540306-A024-4DEA-A835-391C028B26A9Q35841201-C653EE4D-C615-4157-B8AD-93213EAB3F8CQ36307061-1800CB54-0DDE-452A-A64E-86554DACA23AQ36332395-640D48E2-D9BB-4E1F-AB48-003DD529E99EQ36729910-E87BB983-5823-4AB5-90D3-991728318783Q36729984-20FA2877-CB36-4230-B83F-0027B7A74A71Q36871618-5F9D8D11-D077-4B0B-934F-0CEFEE5D49DAQ37031309-3E757481-542F-4D14-A33F-D22A003679CAQ37117608-000A627C-E317-4BC0-99E4-B8964424576FQ37412469-22C28F74-3DD9-4C9E-94E4-5DFE2282533CQ37435688-9F90FF61-10AE-4920-90F3-146495B90368Q37729773-8230FD4B-B8DF-454B-84F5-A4F347255E09Q37995315-1D7131A0-5180-4D17-BE2A-143E9BC5EBCAQ38113494-85D9A40A-805E-4E5F-A87E-ECEE5E6CFD37Q38191275-2428D541-4E40-4B14-A491-26A5D504CCBBQ38200826-C1B78BE4-1E6C-425A-93E2-7886EB46130FQ38222135-6AF8E8A7-295B-4D71-91B3-5007A44F9E9DQ38268344-F612EB76-686E-4085-92A2-AF59FA94768DQ38599323-10EDA8EB-E5FE-4465-A7E4-ACAEED7EBC5DQ39587082-0AC559D6-CD8C-49C2-9FB6-AFACC0C7BE53Q39918625-3CCAF0C7-0645-4472-A665-05CF1526A5A5Q42410902-3E2EEF60-5082-4087-BDB5-3E4ADBD7A56EQ45342111-7DB00A20-408F-4285-8FE7-AD79906B7C41Q47146839-F772E1DB-2FFA-4E42-8F2C-EACC97A63D3DQ48168322-6A552224-CAF3-4E0D-A0D2-EE7FA68071D2Q50858431-952D8B6B-AD9A-488E-8C5B-EF89CB1444FDQ52861582-C112520F-3287-4826-93E5-76BB7426237CQ59111383-BD01B036-0EBD-4F59-BDDC-E7A77EB7C3A4
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Are statins diabetogenic?
@ast
Are statins diabetogenic?
@en
Are statins diabetogenic?
@nl
type
label
Are statins diabetogenic?
@ast
Are statins diabetogenic?
@en
Are statins diabetogenic?
@nl
prefLabel
Are statins diabetogenic?
@ast
Are statins diabetogenic?
@en
Are statins diabetogenic?
@nl
P2093
P2860
P3181
P1476
Are statins diabetogenic?
@en
P2093
Macrae F Linton
Sergio Fazio
Uchechukwu K Sampson
P2860
P3181
P356
10.1097/HCO.0B013E3283470359
P407
P577
2011-07-01T00:00:00Z